JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tolvanen, T.
Right arrow Articles by Minn, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tolvanen, T.
Right arrow Articles by Minn, H.

18F-Fluoroerythronitroimidazole Radiation Dosimetry in Cancer Studies

Tuula Tolvanen, MSc1, Kaisa Lehtiö, MD1, Jarmo Kulmala, PhD2, Vesa Oikonen, MSc1, Olli Eskola, MSc3, Jörgen Bergman, MSc3 and Heikki Minn, MD1

1 Turku PET Centre, Turku University Central Hospital, Turku, Finland
2 Department of Oncology and Radiotherapy, Turku University Central Hospital, Turku, Finland
3 Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, Turku, Finland



View larger version (12K):

[in a new window]
  		FIGURE 1. Dynamic imaging protocols used for 18F-FETNIM PET dosimetric study. Protocol 1 was used specifically to measure source organ uptake in thorax and abdomen. Protocols 2 and 3 were used in head and neck cancer patients. Frame rates varied in 3 protocols and are explained in text. Tr = transmission scan.

 


View larger version (18K):

[in a new window]
  		FIGURE 2. Activity of 18F-FETNIM in 4 source organs shows clearly higher activity than rest of body: blood, spleen, liver, and kidneys. Solid line is mean curve of individual values. Activity has been normalized to 1-MBq injected dose and 70-kg body weight. Similar shape in curves for blood, liver, and spleen indicates that blood activity has major impact on dose of 2 parenchymal organs.

 


View larger version (19K):

[in a new window]
  		FIGURE 3. Activity of 18F-FETNIM in source organs shows relatively low activity: muscle, brain, bone marrow, and lung. Solid line is mean curve of individual values. Activity has been normalized to 1-MBq injected dose and 70-kg body weight.

 


View larger version (12K):

[in a new window]
  		FIGURE 4. 18F-FETNIM urine activity. Fitted curve is based on 28 samples from 27 patients. Note high percentage of total injected activity excreted in bladder for subjects holding urine. ID = injected dose.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.